Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Moderna (MRNA) a catalyst driven idea at Morgan Stanley
January 6, 2023 12:17 PM ESTMorgan Stanley analyst Matthew Harrison labeled Moderna (NASDAQ: MRNA) a Catalyst Driven Idea in a note Friday, maintaining an Equal-Weight rating and $209 price target on the stock.
The analyst told investors the firm expects Moderna's first interim analysis from its Ph3 RSV vaccine study in the near term.
"We believe efficacy and... More
CytomX Therapeutics (CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics
January 5, 2023 4:37 PM ESTCytomX Therapeutics (NASDAQ: CTMX) Climbs 50% Following Pact with Moderna on Collaboration for mRNA-Based Conditionally Activated Therapeutics
... MoreMorgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More
